Taking on board COVID-19 vaccine approval euphoria plus growth prospects
30/12/20 -"With UK’s emergency use approval for Astra-Oxford’s COVID-19 vaccine candidate, the sentiment around Astra’s share price should improve finally. Besides taking on board the 100% probability of ..."
Pages
66
Language
English
Published on
30/12/20
You may also be interested by these reports :
12/02/26
Ipsen concluded 2025 with sales and profitability exceeding expectations, driven by growth across all therapeutic areas. The 2026 guidance surpassed ...
12/02/26
Since the beginning of 2025, and even after the new CEO (Maziar Mike Doustdar) was appointed in August 2025, Novo has downgraded growth expectations ...
10/02/26
Even though Q4 25 operating profitability missed the street’s expectations, Astra met its full-year CER guidance. The Q4 performance was largely ...
06/02/26
Q4 ‘25 results exceeded consensus, as Lundbeck met its 2025 guidance. Strong growth for depression treatment Rexulti and migraine medicine Vyepti ...